Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoPrecise Antibodies Ltd.

< Previous 1 2 Next >
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Key Leadership Changes
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Resignation of Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Present at The Microcap Conference 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.